Lack of association between cortical amyloid deposition and glucose metabolism in early stage Alzheimer´s disease patients

1Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science 1992; 256: 184-5. doi: 10.1126/science.1566067Hardy JA Higgins GA Alzheimer’s disease: the amyloid cascade hypothesis Science 1992 256 184 5 10.1126/science.15660671566067Open DOISearch in Google Scholar

2Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 2002; 297: 353-6. doi: 10.1126/science.1072994Hardy J Selkoe DJ The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics Science 2002 297 353 6 10.1126/science.107299412130773Open DOISearch in Google Scholar

3Murphy MP, LeVine H. Alzheimer’s disease and the amyloid-beta peptide. J Alzheimers Dis 2010; 19: 311-23. doi: 10.3233/JAD-2010-1221Murphy MP LeVine H Alzheimer’s disease and the amyloid-beta peptide J Alzheimers Dis 2010 19 311 23 10.3233/JAD-2010-1221281350920061647Open DOISearch in Google Scholar

4Jack CR Jr, Wiste HJ, Knopman DS, Vemuri P, Mielke MM, Weigand SD, et al. Rates of beta-amyloid accumulation are independent of hippocampal neurodegeneration. Neurology 2014; 82: 1605-12. doi: 10.1212/WNL.0000000000000386Jack CR Jr Wiste HJ Knopman DS Vemuri P Mielke MM Weigand SD et al Rates of beta-amyloid accumulation are independent of hippocampal neurodegeneration Neurology 2014 82 1605 12 10.1212/WNL.0000000000000386401381024706010Open DOISearch in Google Scholar

5Altmann A, Ng B, Landau SM, Jagust WJ, Greicius MD. Regional brain hypometabolism is unrelated to regional amyloid plaque burden. Brain 2015; 138: 3734-46. doi: 10.1093/brain/awv278Altmann A Ng B Landau SM Jagust WJ Greicius MD Regional brain hypometabolism is unrelated to regional amyloid plaque burden Brain 2015 138 3734 46 10.1093/brain/awv278480671826419799Open DOISearch in Google Scholar

6Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al; Bapineuzumab 301 and 302 Clinical Trial Investigators. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med 2014; 370: 322-33. doi: 10.1056/NEJMoa1304839Salloway S Sperling R Fox NC Blennow K Klunk W Raskind M et al; Bapineuzumab 301 and 302 Clinical Trial Investigators Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease N Engl J Med 2014 370 322 33 10.1056/NEJMoa1304839415961824450891Open DOISearch in Google Scholar

7Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol 2012; 71: 36281. doi: 10.1097/NEN.0b013e31825018f7Nelson PT Alafuzoff I Bigio EH Bouras C Braak H Cairns NJ et al Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature J Neuropathol Exp Neurol 2012 71 36281 10.1097/NEN.0b013e31825018f7356029022487856Open DOISearch in Google Scholar

8Cho H, Choi JY, Hwang MS, Lee JH, Kim YJ, Lee HM, et al. Tau PET in Alzheimer disease and mild cognitive impairment. Neurology 2016; 87: 375-83. doi: 10.1212/WNL.0000000000002892Cho H Choi JY Hwang MS Lee JH Kim YJ Lee HM et al Tau PET in Alzheimer disease and mild cognitive impairment Neurology 2016 87 375 83 10.1212/WNL.000000000000289227358341Open DOISearch in Google Scholar

9Schöll M, Ossenkoppele R, Strandberg O, Palmqvist S, Jögi J, Ohlsson T, et al. Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer’s disease. Brain 2017; 140: 2286-94. doi: 10.1093/brain/awx171Schöll M Ossenkoppele R Strandberg O Palmqvist S Jögi J Ohlsson T et al Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer’s disease Brain 2017 140 2286 94 10.1093/brain/awx17129050382Open DOISearch in Google Scholar

10Saint-Aubert L, Almkvist O, Chiotis K, Almeida R, Wall A, Nordberg A. Regional tau deposition measured by [18F]THK5317 positron emission tomography is associated to cognition via glucose metabolism in Alzheimer’s disease. Alzheimers Res Ther 2016; 8: 38. doi: 10.1186/s13195-016-0204-zSaint-Aubert L Almkvist O Chiotis K Almeida R Wall A Nordberg A Regional tau deposition measured by [18F]THK5317 positron emission tomography is associated to cognition via glucose metabolism in Alzheimer’s disease Alzheimers Res Ther 2016 8 38 10.1186/s13195-016-0204-z504151627683159Open DOISearch in Google Scholar

11Jack CR Jr, Petersen RC, Xu YC, O’Brien PC, Smith GE, Ivnik RJ, et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 1999; 52: 1397-403.Jack CR Jr Petersen RC Xu YC O’Brien PC Smith GE Ivnik RJ et al Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment Neurology 1999 52 1397 40310.1212/WNL.52.7.1397Search in Google Scholar

12Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol 2013; 12: 357-67. doi: 10.1016/S1474-4422(13)70044-9Villemagne VL Burnham S Bourgeat P Brown B Ellis KA Salvado O et al Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol 2013 12 357 67 10.1016/S1474-4422(13)70044-9Open DOISearch in Google Scholar

13McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7: 263-9. doi: 10.1016/j.jalz.2011.03.005McKhann GM Knopman DS Chertkow H Hyman BT Jack CR Jr Kawas CH et al The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease Alzheimers Dement 2011 7 263 9 10.1016/j.jalz.2011.03.005Open DOISearch in Google Scholar

14Shivamurthy VK, Tahari AK, Marcus C, Subramaniam RM. Brain FDG PET and the diagnosis of dementia. AJR Am J Roentgenol 2015; 204: W76-85. doi: 10.2214/AJR.13.12363Shivamurthy VK Tahari AK Marcus C Subramaniam RM Brain FDG PET and the diagnosis of dementia AJR Am J Roentgenol 2015 204 W76 85 10.2214/AJR.13.12363Open DOISearch in Google Scholar

15Ishii K. PET approaches for diagnosis of dementia. AJNR Am J Neuroradiol 2014; 35: 2030-8. doi: 10.3174/ajnr.A3695Ishii K PET approaches for diagnosis of dementia AJNR Am J Neuroradiol 2014 35 2030 8 10.3174/ajnr.A3695Open DOISearch in Google Scholar

16Shaffer JL, Petrella JR, Sheldon FC, Choudhury KR, Calhoun VD, Coleman RE, et al. Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined. Radiology 2013; 266: 583-91. doi: 10.1148/radiol.12120010Shaffer JL Petrella JR Sheldon FC Choudhury KR Calhoun VD Coleman RE et al Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined Radiology 2013 266 583 91 10.1148/radiol.12120010Open DOISearch in Google Scholar

17Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer’s disease. Brain 2006; 129: 2856-66. doi: 10.1093/brain/awl178Engler H Forsberg A Almkvist O Blomquist G Larsson E Savitcheva I et al Two-year follow-up of amyloid deposition in patients with Alzheimer’s disease Brain 2006 129 2856 66 10.1093/brain/awl178Open DOISearch in Google Scholar

18Edison P, Archer HA, Hinz R, Hammers A, Pavese N, Tai YF, et al. Amyloid, hypometabolism, and cognition in Alzheimer disease: An [11C]PIB and [18F]FDG PET study. Neurology 2007; 68: 501-8. doi: 10.1212/01.wnl.0000244749.20056.d4Edison P Archer HA Hinz R Hammers A Pavese N Tai YF et al Amyloid, hypometabolism, and cognition in Alzheimer disease: An [11C]PIB and [18F]FDG PET study Neurology 2007 68 501 8 10.1212/01.wnl.0000244749.20056.d4Open DOISearch in Google Scholar

19Cohen AD, Price JC, Weissfeld LA, James J, Rosario BL, Bi W, et al. Basal cerebral metabolism may modulate the cognitive effects of Aβ in mild cognitive impairment: an example of brain reserve. J Neurosci 2009; 29: 14770-8. doi: 10.1523/JNEUROSCI.3669-09.2009Cohen AD Price JC Weissfeld LA James J Rosario BL Bi W et al Basal cerebral metabolism may modulate the cognitive effects of Aβ in mild cognitive impairment: an example of brain reserve J Neurosci 2009 29 14770 8 10.1523/JNEUROSCI.3669-09.2009Open DOISearch in Google Scholar

20Deuschl G, Maier W, et al; Steuerungsgruppe. S3- Guideline dementias. [German]. In: German Society for Neurology, editor. Guidelines for diagnostics and therapy in neurology. [German]. 2016. [cited 2021 Sep 12]. Available at: www.dgn.org/leitlinienDeuschl G Maier W et al; Steuerungsgruppe S3- Guideline dementias [German]. In: German Society for Neurology, editor. Guidelines for diagnostics and therapy in neurology. [German] 2016 [cited 2021 Sep 12]. Available at www.dgn.org/leitlinienSearch in Google Scholar

21Folstein MF, Folsten SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98. doi: 10.1016/0022-3956(75)90026-6Folstein MF Folsten SE McHugh PR Mini-mental state: a practical method for grading the cognitive state of patients for the clinician J Psychiatr Res 1975 12 189 98 10.1016/0022-3956(75)90026-6Open DOISearch in Google Scholar

22Pichler R, Dunzinger A, Wurm G, Pichler J, Weis S, Nussbaumer K, et al. Is there a place for FET PET in the initial evaluation of brain lesions with unknown significance? Eur J Nucl Med Mol Imaging 2010; 37: 1521-8. doi: 10.1007/s00259-010-1457-6Pichler R Dunzinger A Wurm G Pichler J Weis S Nussbaumer K et al Is there a place for FET PET in the initial evaluation of brain lesions with unknown significance? Eur J Nucl Med Mol Imaging 2010 37 1521 8 10.1007/s00259-010-1457-6Open DOISearch in Google Scholar

23Hodolic M, Topakian R, Pichler R. 18F-fluorodeoxyglucose and 18F-flumazenil positron emission tomography in patients with refractory epilepsy. Radiol Oncol 2016; 50: 247-53. doi: 10.1515/raon-2016-0032Hodolic M Topakian R Pichler R 18F-fluorodeoxyglucose and 18F-flumazenil positron emission tomography in patients with refractory epilepsy Radiol Oncol 2016 50 247 53 10.1515/raon-2016-0032Open DOISearch in Google Scholar

24R Core Team. A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2019. [cited 2021 Sep 13]. Available at: http://www.R-project.org/R Core Team A language and environment for statistical computing Vienna, Austria: R Foundation for Statistical Computing; 2019 [cited 2021 Sep 13]. Available at http://www.R-project.org/Search in Google Scholar

25Holm S. A simple sequentially rejective multiple test procedure. Scand J of Stat 1979; 6: 65-70.Holm S A simple sequentially rejective multiple test procedure Scand J of Stat 1979 6 65 70Search in Google Scholar

26Murphy MP, LeVine H. Alzheimer’s disease and the amyloid-beta peptide. J Alzheimers Dis 2010; 19: 311-23. doi: 10.3233/JAD-2010-1221Murphy MP LeVine H Alzheimer’s disease and the amyloid-beta peptide J Alzheimers Dis 2010 19 311 23 10.3233/JAD-2010-1221Open DOISearch in Google Scholar

27Dickson TC, Vickers JC. The morphological phenotype of beta-amyloid plaques and associated neuritic changes in Alzheimer’s disease. Neuroscience 2001; 105: 99-107. doi: 10.1016/s0306-4522(01)00169-5Dickson TC Vickers JC The morphological phenotype of beta-amyloid plaques and associated neuritic changes in Alzheimer’s disease Neuroscience 2001 105 99 107 10.1016/s0306-4522(01)00169-5Open DOISearch in Google Scholar

28Vlassenko AG, Benzinger TL, Morris JC. PET amyloid-beta imaging in preclinical Alzheimer’s disease. Biochim Biophys Acta 12012; 1822: 370-9. doi: 10.1016/j.bbadis.2011.11.005Vlassenko AG Benzinger TL Morris JC PET amyloid-beta imaging in preclinical Alzheimer’s disease Biochim Biophys Acta 12012; 1822 370 9 10.1016/j.bbadis.2011.11.005326479022108203Open DOISearch in Google Scholar

29Lowe SL, Willis BA, Hawdon A, Natanegara F, Chua L, Foster J, et al. Donanemab (LY3002813) dose-escalation study in Alzheimer’s disease. Alzheimers Dement (N Y) 7: e12112. doi: 10.1002/trc2.12112Lowe SL Willis BA Hawdon A Natanegara F Chua L Foster J et al Donanemab (LY3002813) dose-escalation study in Alzheimer’s disease Alzheimers Dement (N Y) 7 e12112 10.1002/trc2.12112788253233614890Open DOISearch in Google Scholar

30Huang LK, Chao SP, Hu CJ. Clinical trials of new drugs for Alzheimer disease. J Biomed Sci 2020; 27: 18. doi: 10.1186/s12929-019-0609-7Huang LK Chao SP Hu CJ Clinical trials of new drugs for Alzheimer disease J Biomed Sci 2020 27 18 10.1186/s12929-019-0609-7694390331906949Open DOISearch in Google Scholar

31Tomic JL, Pensalfini A, Head E, Glabe CG. Soluble fibrillar oligomer levels are elevated in Alzheimer’s disease brain and correlate with cognitive dysfunction. Neurobiol Dis 2009; 35: 352-8. doi: 10.1016/j.nbd.2009.05.024Tomic JL Pensalfini A Head E Glabe CG Soluble fibrillar oligomer levels are elevated in Alzheimer’s disease brain and correlate with cognitive dysfunction Neurobiol Dis 2009 35 352 8 10.1016/j.nbd.2009.05.024272519919523517Open DOISearch in Google Scholar

32Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Cedarbaum J, et al. 2014 Update of the Alzheimer’s Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement 2015; 11: e1-120. doi: 10.1016/j.jalz.2014.11.001Weiner MW Veitch DP Aisen PS Beckett LA Cairns NJ Cedarbaum J et al 2014 Update of the Alzheimer’s Disease Neuroimaging Initiative: a review of papers published since its inception Alzheimers Dement 2015 11 e1 120 10.1016/j.jalz.2014.11.001546929726073027Open DOISearch in Google Scholar

33Small GW, Kepe V, Ercoli LM, Siddarth P, Bookheimer SY, Miller KJ, et al. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med 2006; 355: 2652-63. doi: 10.1056/NEJMoa054625Small GW Kepe V Ercoli LM Siddarth P Bookheimer SY Miller KJ et al PET of brain amyloid and tau in mild cognitive impairment N Engl J Med 2006 355 2652 63 10.1056/NEJMoa05462517182990Open DOISearch in Google Scholar

34Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O’Keefe G, et al. Imaging of amyloid beta in Alzheimer’s disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol 2008; 7: 129-35. doi: 10.1016/S1474-4422(08)70001-2Rowe CC Ackerman U Browne W Mulligan R Pike KL O’Keefe G et al Imaging of amyloid beta in Alzheimer’s disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism Lancet Neurol 2008 7 129 35 10.1016/S1474-4422(08)70001-2Open DOISearch in Google Scholar

35Koole M, Lewis DM, Buckley C, Nelissen N, Vandenbulcke M, Brooks DJ, et al. Whole-body biodistribution and radiation dosimetry of 18F-GE067: a radioligand for in vivo brain amyloid imaging. J Nucl Med 2009; 50: 818-22. doi: 10.2967/jnumed.108.060756Koole M Lewis DM Buckley C Nelissen N Vandenbulcke M Brooks DJ et al Whole-body biodistribution and radiation dosimetry of 18F-GE067: a radioligand for in vivo brain amyloid imaging J Nucl Med 2009 50 818 22 10.2967/jnumed.108.06075619372469Open DOISearch in Google Scholar

36Kung HF, Choi SR, Qu W, Zhang W, Skovronsky D. 18F stilbenes and styrylpyridines for PET imaging of a beta plaques in Alzheimer’s disease: a miniperspective. J Med Chem 2010; 53: 933-41. doi: 10.1021/jm901039zKung HF Choi SR Qu W Zhang W Skovronsky D 18F stilbenes and styrylpyridines for PET imaging of a beta plaques in Alzheimer’s disease: a miniperspective J Med Chem 2010 53 933 41 10.1021/jm901039z281833519845387Open DOISearch in Google Scholar

37Frings L, Hellwig S, Spehl TS, Bormann T, Buchert R, Vach W, et al. Asymmetries of amyloid-β burden and neuronal dysfunction are positively correlated in Alzheimer’s disease. Brain 2015; 138: 3089-99. doi: 10.1093/brain/awv229Frings L Hellwig S Spehl TS Bormann T Buchert R Vach W et al Asymmetries of amyloid-β burden and neuronal dysfunction are positively correlated in Alzheimer’s disease Brain 2015 138 3089 99 10.1093/brain/awv22926280595Open DOISearch in Google Scholar

38Jack CR Jr, Wiste HJ, Knopman DS, Vemuri P, Mielke MM, Weigand SD, et al. Rates of beta-amyloid accumulation are independent of hippocampal neurodegeneration. Neurology 2014; 82: 1605-12. doi: 10.1212/WNL.0000000000000386Jack CR Jr Wiste HJ Knopman DS Vemuri P Mielke MM Weigand SD et al Rates of beta-amyloid accumulation are independent of hippocampal neurodegeneration Neurology 2014 82 1605 12 10.1212/WNL.0000000000000386401381024706010Open DOISearch in Google Scholar

39Scahill RI, Schott JM, Stevens JM, Rossor MN, Fox NC. Mapping the evolution of regional atrophy in Alzheimer’s disease: unbiased analysis of fluid-registered serial MRI. Proc Natl Acad Sci USA 2002; 99: 4703-7. doi: 10.1073/pnas.052587399Scahill RI Schott JM Stevens JM Rossor MN Fox NC Mapping the evolution of regional atrophy in Alzheimer’s disease: unbiased analysis of fluid-registered serial MRI Proc Natl Acad Sci USA 2002 99 4703 7 10.1073/pnas.05258739912371111930016Open DOISearch in Google Scholar

40Pearson RC, Esiri MM, Hiorns RW, Wilcock GK, Powell TP. Anatomical correlates of the distribution of the pathological changes in the neocortex in Alzheimer disease. Proc Natl Acad Sci USA 1985; 82: 4531-4. doi: 10.1073/pnas.82.13.4531Pearson RC Esiri MM Hiorns RW Wilcock GK Powell TP Anatomical correlates of the distribution of the pathological changes in the neocortex in Alzheimer disease Proc Natl Acad Sci USA 1985 82 4531 4 10.1073/pnas.82.13.45313911363859874Open DOISearch in Google Scholar

41Kepe V, Moghbel MC, Långström B, Zaidi H, Vinters HV, Huang SC, et al. Amyloid-β positron emission tomography imaging probes: a critical review. J Alzheimers Dis 2013; 36: 613-31. doi: 10.3233/JAD-130485Kepe V Moghbel MC Långström B Zaidi H Vinters HV Huang SC et al Amyloid-β positron emission tomography imaging probes: a critical review J Alzheimers Dis 2013 36 613 31 10.3233/JAD-130485374001523648516Open DOISearch in Google Scholar

42Zwan MD, Bouwman FH, Konijnenberg E, van der Flier WM, Lammmertma AA, Verhey FR, et al. Diagnostic impact of [18F]flutemetamol PET in earlyonset dementia. Alzheimers Res Ther 2017; 9: 2. doi: 10.1186/s13195-0160228-4Zwan MD Bouwman FH Konijnenberg E van der Flier WM Lammmertma AA Verhey FR et al Diagnostic impact of [18F]flutemetamol PET in earlyonset dementia Alzheimers Res Ther 2017 9 2 10.1186/s13195-0160228-4Open DOISearch in Google Scholar

43Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239-59. doi: 10.1007/BF00308809Braak H Braak E Neuropathological stageing of Alzheimer-related changes Acta Neuropathol 1991 82 239 59 10.1007/BF003088091759558Open DOISearch in Google Scholar

44Morbelli S, Bauckneht M, Scheltens P. Imaging biomarkers in Alzheimer’s Disease: added value in the clinical setting. Q J Nucl Med Mol Imaging 2017; 61: 360-71. doi: 10.23736/S1824-4785.17.03011-4Morbelli S Bauckneht M Scheltens P Imaging biomarkers in Alzheimer’s Disease: added value in the clinical setting Q J Nucl Med Mol Imaging 2017 61 360 71 10.23736/S1824-4785.17.03011-428750495Open DOISearch in Google Scholar

45Bennett DA, Schneider JA, Wilson RS, Bienias JL, Arnold SE. Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch Neurol 2004; 61: 378-84. doi: 10.1001/archneur.61.3.378Bennett DA Schneider JA Wilson RS Bienias JL Arnold SE Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function Arch Neurol 2004 61 378 84 10.1001/archneur.61.3.37815023815Open DOISearch in Google Scholar

46Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, et al. Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory. Nat Med 2008; 14: 837-42. doi: 10.1038/nm1782Shankar GM Li S Mehta TH Garcia-Munoz A Shepardson NE Smith I et al Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory Nat Med 2008 14 837 42 10.1038/nm1782277213318568035Open DOISearch in Google Scholar

47Braak H, Alafuzoff I, Arzberger T, Kretzschmanr H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunhistochemistry. Acta Neuropathol 2006; 112: 389-404. doi: 10.1007/s00401-006-0127-zBraak H Alafuzoff I Arzberger T Kretzschmanr H Del Tredici K Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunhistochemistry Acta Neuropathol 2006 112 389 404 10.1007/s00401-006-0127-z390670916906426Open DOISearch in Google Scholar

48Dronse J, Fliessbach K, Bischof GN, Reutern von B, Faber J, Hammes J, et al. In vivo patterns of tau pathology, amyloid-β burden, and neuronal dysfunction in clinical variants of Alzheimer’s disease. J Alzheimers Dis 2017; 55: 465-71. doi: 10.3233/JAD-160316Dronse J Fliessbach K Bischof GN Reutern von B Faber J Hammes J et al In vivo patterns of tau pathology, amyloid-β burden, and neuronal dysfunction in clinical variants of Alzheimer’s disease J Alzheimers Dis 2017 55 465 71 10.3233/JAD-16031627802224Open DOISearch in Google Scholar

49Bejanin A, Schonhaut DR, La Joie R, Kramer JH, Baker SL, Sosa N, et al. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer’s disease. Brain 2017; 140: 3286-300. doi: 10.1093/brain/awx243Bejanin A Schonhaut DR La Joie R Kramer JH Baker SL Sosa N et al Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer’s disease Brain 2017 140 3286 300 10.1093/brain/awx243584113929053874Open DOISearch in Google Scholar

50Huber CM, Yee C, May T, Dhanala A, Mitchell CS. Cognitive decline in preclinical Alzheimer’s disease: amyloid-beta versus tauopathy. J Alzheimers Dis 2018; 61: 265-81. doi: 10.3233/JAD-170490Huber CM Yee C May T Dhanala A Mitchell CS Cognitive decline in preclinical Alzheimer’s disease: amyloid-beta versus tauopathy J Alzheimers Dis 2018 61 265 81 10.3233/JAD-170490573413129154274Open DOISearch in Google Scholar